Novartis Says Accord Can't Make, Sell Generic Bone Drug

Law360, Los Angeles (November 27, 2013, 4:34 PM ET) -- Novartis Pharmaceuticals Corp. hit Accord Healthcare Inc. with a patent infringement lawsuit in New Jersey federal court on Tuesday, saying Accord asked the U.S. Food and Drug Administration to approve generic versions of Novartis’ bone drug Zometa prior to the expiration of a patent that protects it.

Novartis seeks to enforce its rights to Zometa, which was first approved by the FDA in 2001 and is approved to treat hypercalcemia of malignancy, a condition resulting in high calcium blood levels due to cancer, multiple myeloma and...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required